You are here:

Forthcoming Submission: midostaurin (Rydapt) for AML

Indication: Treatment of adult patients with newly diagnosed acute myeloid leukaemia who are FLT3 mutation positive in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy.

Drug Details

Drug Name: midostaurin (Rydapt) for AML
Drug Manufacturer: Novartis Pharmaceuticals UK Ltd
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
5/03/2018
SMC Meeting Date: Q2 2018
Advice Due: Q2 2018

Back